ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 18.5 USD 0.54% Market Closed
Market Cap: 4.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

ADMA Price Targets Summary
ADMA Biologics Inc

Wall Street analysts forecast ADMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADMA is 30.08 USD with a low forecast of 21.17 USD and a high forecast of 36.75 USD.

ADMA Lowest Forecast
Wall Street Target
21.17 USD
14% Upside
ADMA Average Forecast
Wall Street Target
30.08 USD
63% Upside
ADMA Highest Forecast
Wall Street Target
36.75 USD
99% Upside
Lowest
Price Target
21.17 USD
14% Upside
Average
Price Target
30.08 USD
63% Upside
Highest
Price Target
36.75 USD
99% Upside
ADMA Biologics Inc Competitors:
Price Targets
LYEL
Lyell Immunopharma Inc
79% Upside
AGIO
Agios Pharmaceuticals Inc
63% Upside
S
688293
Shanghai OPM Biosciences Co Ltd
35% Upside
688331
RemeGen Co Ltd
25% Downside
LYEL
Lyell Immunopharma Inc
79% Upside
AGIO
Agios Pharmaceuticals Inc
63% Upside
S
688293
Shanghai OPM Biosciences Co Ltd
35% Upside
688331
RemeGen Co Ltd
25% Downside
GLPG
Galapagos NV
26% Upside
CDNA
CareDx Inc
53% Upside
K
4584
Kidswell Bio Corporation
60% Upside
AKBA
Akebia Therapeutics Inc
102% Upside

Revenue
Forecast

Revenue Estimate
ADMA Biologics Inc

For the last 8 years the compound annual growth rate for ADMA Biologics Inc's revenue is 59%. The projected CAGR for the next 3 years is 26%.

59%
Past Growth
26%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ADMA Biologics Inc

The compound annual growth rate of ADMA Biologics Inc's operating income for the next 3 years is 44%.

N/A
Past Growth
44%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
ADMA Biologics Inc

The compound annual growth rate of ADMA Biologics Inc's net income for the next 3 years is 19%.

N/A
Past Growth
19%
Estimated Growth
Estimates Accuracy
-64%
Average Miss
What are analyst estimates?

See Also

Summary
ADMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADMA stock valuation using valuation multiples.
Wall Street Estimates
ADMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ADMA's stock price target?
Price Target
30.08 USD

According to Wall Street analysts, the average 1-year price target for ADMA is 30.08 USD with a low forecast of 21.17 USD and a high forecast of 36.75 USD.

What is ADMA Biologics Inc's Revenue forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for ADMA Biologics Inc's revenue is 59%. The projected CAGR for the next 3 years is 26%.

What is ADMA Biologics Inc's Operating Income forecast?
Projected CAGR
44%

The compound annual growth rate of ADMA Biologics Inc's operating income for the next 3 years is 44%.

What is ADMA Biologics Inc's Net Income forecast?
Projected CAGR
19%

The compound annual growth rate of ADMA Biologics Inc's net income for the next 3 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 264,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.